Molecular docking and computational pharmacokinetic study of some novel coumarin–benzothiazole schiff’s base for antimicrobial activity
By: Madriwala, Burhanuddin
.
Contributor(s): Jays, Judy.
Publisher: M P Innovare Academic Sciences Pvt Ltd 2022Edition: Vol.14(8), Jun.Description: 16-21p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
International journal of pharmacy and pharmaceutical scienceSummary: Objective: The present study discusses molecular docking of some novel coumarin–benzothiazole Schiffbasesand the prediction ofpharmacokinetic properties of potent molecules bythecomputational method. Methods: Fiveprotein targets were selected for the study andtheir structures were taken from RCSB Protein Data Bank in PDB format. Preparation of proteins was done using Discovery Studio 2021 Client. A totaloftwentyderivatives were drawn using ChemDraw 20.0 and saved in Mol format. Molecular docking was performed using PyRx software. Docking results were visualized byDiscovery Studio 2021 Client. The pharmacokinetic properties of the best compounds were determined using the pkCSM tool.Results: All twenty derivatives were docked against the fiveproteins,namelyDNA Ligase(PDB ID: 3PN1), Topoisomerase (PDB ID: 3TTZ), Sterol demethylase (PDB ID: 5FSA),Enoyl-acyl-carrier protein (PDB ID: 1BVR)and Glutamate racemase (PDB ID: 5HJ7). The compound JJB18 has shown the best binding score against DNA ligase(-10.7 kcal/mol), Glutamate racemase(-8.4 kcal/mol), and Enoyl-acyl-carrier protein(-10.8 kcal/mol). Further, compound JJB19 has shown the best score for fungal sterol demethylase (-10.6 kcal/mol) and compound JJB20 towards topoisomerase (-9.4 kcal/mol)than the standard drugs.The physicochemical properties of potent derivatives were also reported.Conclusion: Molecular Docking study indicates that coumarin–benzothiazole Schiff bases may be effective inhibitors for the different microbial proteins. Additionally, in silicoADMET studies predicts drug-like features. Hence, these compounds may be considered leadmoleculesand further investigation of their analogues may help in the development of novel drugs for the treatment of microbial diseases.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-1909 |
Objective: The present study discusses molecular docking of some novel coumarin–benzothiazole Schiffbasesand the prediction ofpharmacokinetic properties of potent molecules bythecomputational method. Methods: Fiveprotein targets were selected for the study andtheir structures were taken from RCSB Protein Data Bank in PDB format. Preparation of proteins was done using Discovery Studio 2021 Client. A totaloftwentyderivatives were drawn using ChemDraw 20.0 and saved in Mol format. Molecular docking was performed using PyRx software. Docking results were visualized byDiscovery Studio 2021 Client. The pharmacokinetic properties of the best compounds were determined using the pkCSM tool.Results: All twenty derivatives were docked against the fiveproteins,namelyDNA Ligase(PDB ID: 3PN1), Topoisomerase (PDB ID: 3TTZ), Sterol demethylase (PDB ID: 5FSA),Enoyl-acyl-carrier protein (PDB ID: 1BVR)and Glutamate racemase (PDB ID: 5HJ7). The compound JJB18 has shown the best binding score against DNA ligase(-10.7 kcal/mol), Glutamate racemase(-8.4 kcal/mol), and Enoyl-acyl-carrier protein(-10.8 kcal/mol). Further, compound JJB19 has shown the best score for fungal sterol demethylase (-10.6 kcal/mol) and compound JJB20 towards topoisomerase (-9.4 kcal/mol)than the standard drugs.The physicochemical properties of potent derivatives were also reported.Conclusion: Molecular Docking study indicates that coumarin–benzothiazole Schiff bases may be effective inhibitors for the different microbial proteins. Additionally, in silicoADMET studies predicts drug-like features. Hence, these compounds may be considered leadmoleculesand further investigation of their analogues may help in the development of novel drugs for the treatment of microbial diseases.
Click on an image to view it in the image viewer
There are no comments for this item.